Next Generation Sequencing – Biomarker Analysis on Sequence level

TPL Path Labs is extending its services to Next Generation Sequencing (NGS) of Targeted Gene Panels. We will be addressing the mutational status of solid tumours such as melanoma. By installing the Illumina MiniSeq sequencing platform in our emerging, state-of-the-art molecular biology lab, we are opting for one of the most advanced fluorescence-based sequencing technologies available.

For our clients, this opens up a new level of convenience – whether you require the power of NGS as a diagnostic or research tool in addition to immunohistochemistry, in situ hybridisation, fluorescence in situ hybridisation, or toxicological pathology services, TPL is your trusted and reliable partner.